J
Jlenia Brunetti
Researcher at University of Siena
Publications - 63
Citations - 1195
Jlenia Brunetti is an academic researcher from University of Siena. The author has contributed to research in topics: In vivo & Antimicrobial. The author has an hindex of 19, co-authored 55 publications receiving 847 citations.
Papers
More filters
Journal ArticleDOI
Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
Emanuele Andreano,Emanuele Nicastri,Ida Paciello,Piero Pileri,Noemi Manganaro,Giulia Piccini,Alessandro Manenti,Elisa Pantano,Anna Kabanova,Marco Troisi,Fabiola Vacca,Dario Cardamone,Concetta De Santi,Jonathan L. Torres,Gabriel Ozorowski,Linda Benincasa,Hyesun Jang,Cecilia Di Genova,Lorenzo Depau,Jlenia Brunetti,Chiara Agrati,Maria Rosaria Capobianchi,Concetta Castilletti,Arianna Emiliozzi,Massimiliano Fabbiani,Francesca Montagnani,Luisa Bracci,Giuseppe A. Sautto,Ted M. Ross,Emanuele Montomoli,Nigel J. Temperton,Andrew B. Ward,Claudia Sala,Giuseppe Ippolito,Rino Rappuoli +34 more
TL;DR: In this article, a single-cell sorting of 4,277 SARS-CoV-2 spike protein-specific memory B cells from 14 COVID-19 survivors, 453 neutralizing antibodies were identified.
Journal ArticleDOI
A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo
Alessandro Pini,Chiara Falciani,Elisabetta Mantengoli,Stefano Bindi,Jlenia Brunetti,Sara Iozzi,Gian Maria Rossolini,Luisa Bracci +7 more
TL;DR: Pini et al. as mentioned in this paper described the nonnatural antimicrobial peptide KKIRVRLSA (M33) and its capacity to neutralize LPS-induced cytokine release, preventing septic shock in animals infected with bacterial species of clinical interest.
Journal ArticleDOI
In vitro and in vivo efficacy, toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate.
Jlenia Brunetti,Chiara Falciani,Giulia Roscia,Simona Pollini,Stefano Bindi,Silvia Scali,Unai Cossio Arrieta,Vanessa Gómez-Vallejo,Leila Quercini,Elisa Ibba,Marco Prato,Gian Maria Rossolini,Jordi Llop,Luisa Bracci,Alessandro Pini +14 more
TL;DR: In in vivo models of P. aeruginosa infections, the peptide and its pegylated form (SET-M33L-PEG) enabled a survival percentage of 60–80% in sepsis and lung infections when injected twice and proved to have much lower in vivo toxicity than antimicrobial peptides already used in clinical practice.
Journal ArticleDOI
Isomerization of an Antimicrobial Peptide Broadens Antimicrobial Spectrum to Gram-Positive Bacterial Pathogens
Chiara Falciani,Luisa Lozzi,Simona Pollini,Vincenzo Luca,Veronica Carnicelli,Jlenia Brunetti,Barbara Lelli,Stefano Bindi,Silvia Scali,Antonio Di Giulio,Gian Maria Rossolini,Maria Luisa Mangoni,Luisa Bracci,Alessandro Pini +13 more
TL;DR: An M33 peptide isomer consisting of D-aminoacids (M33-D) showed 4 to 16-fold higher activity against Gram-positive pathogens, including Staphylococcus aureus and Staphlyococcus epidermidis, than the original peptide, while retaining strong activity against gram-negative bacteria.
Journal ArticleDOI
Synthesis and biological activity of stable branched neurotensin peptides for tumor targeting.
Chiara Falciani,Monica Fabbrini,Alessandro Pini,Luisa Lozzi,Barbara Lelli,Silvia Pileri,Jlenia Brunetti,Stefano Bindi,Silvia Scali,Luisa Bracci +9 more
TL;DR: It is shown that neurotensin and other endogenous peptides, when synthesized as dendrimers, retain biological activity and become resistant to proteolysis in a tetrabranched form linked to different units for tumor therapy or diagnosis.